Acetylspiramycin pharma grade API is supplied as a 16-membered macrolide antibiotic substance derived from spiramycin, intended only for solid oral and injectable finished dosage form manufacturing. Compendial release of the API is maintained against the current Chinese Pharmacopoeia Acetylspiramycin monograph and, where applicable, the Japanese Pharmacopoeia monograph; ICH Q7 quality systems, ICH Q3C (R8) residual solvent limits, and ICH Q3D (R2) elemental impurity control are applied at the API level. The downstream routes described below are limited to tableting, capsule filling, dry suspension granulation, sterile powder filling, and functional film coating; no veterinary or non-drug applications are included because this pharmacopoeial substance is not marketed for those purposes.

During wet granulation of acetylspiramycin tablet cores, the dominant process constraint is the alkaline hydrolysis of the acetyl ester substituent on the 16-membered macrolide lactone. Aqueous granulation fluid is therefore prepared with purified water at a pH below 7.0, and the wet mass is transferred to the dryer within 30 min in validated production runs to limit de-esterification to spiramycin-related impurities. For a 200 mg label claim, the API fraction in an unlubricated core is typically held between 45 wt% and 60 wt% when the target core mass is 350–400 mg; a 100 mg label claim may require 20–35 wt% drug loading depending on the true density and flow of the diluent system. The exact ratio must be confirmed by excipient compatibility and dose-proportionality data under ICH Q8(R2) design-space methodology. Granulation is performed in a high-shear mixer-granulator at impeller tip speeds of 3–6 m/s and wet massing times of 2–5 min, with pregelatinized starch or copovidone as binder dissolved in the granulating fluid at 3–6 wt% of dry material. The granulate is dried in a fluid-bed dryer with inlet air at 55–65 °C and bed temperature not exceeding 45 °C, because the acetyl ester linkage shows heat-promoted hydrolysis when product temperature rises above this boundary. Drying endpoint is determined by loss on drying according to USP <921> or Ph. Eur. 2.2.32; granules exceeding 3.0% w/w moisture are re-dried, while granules dried below 1.0% w/w can generate excessive fines and subsequent content uniformity drift. Magnesium stearate is added at 0.5–1.0 wt% of the core mass as boundary lubricant in a diffusion mixer at 10–15 rpm; blending beyond 5 min is avoided because over-lubrication delays dissolution by forming hydrophobic surfaces on the granule. Compression is carried out on a rotary tablet press with pre-compression force of 3–5 kN and main compression force of 8–15 kN, using flat-faced bevel-edged tooling. Tablet hardness is controlled between 60 N and 100 N, and friability is maintained below 1.0% per USP <1216>. Production-scale sticking has been observed when ambient relative humidity exceeds 60% RH and granule moisture exceeds 2.0% w/w; therefore humidity-controlled transfer is required between granulation and compression. Compliance for the finished tablet includes the ChP 2020 Acetylspiramycin Tablets monograph, ICH Q3C (R8) for residual binder solvents, ICH Q3D (R2) for elemental impurities, USP <905> for uniformity of dosage units, and USP <711> for dissolution. Terminal finished product types include plain film-coated tablets at 100 mg and 200 mg, as well as tablet cores intended for subsequent functional coating or for unit-dose blister and HDPE bottle packaging.

What Powder Densification Route Prevents Segregation in Acetylspiramycin Capsule Fill Blends?

Capsule filling of acetylspiramycin pharma grade API without prior densification is avoided in production when the API lot exhibits a bulk density below 0.35 g/cm³ and a laser diffraction median particle size d50 under 30 µm. Under those conditions, the fine API fraction segregates from free-flowing lactose monohydrate or microcrystalline cellulose during hopper discharge, producing content uniformity failures at the beginning and end of the encapsulation run. For a size 0 hard capsule with fill mass between 250 mg and 350 mg, a 200 mg label claim corresponds to an API fraction of 57–80 wt%; a 100 mg label claim in a size 1 or size 2 capsule may fall to 25–40 wt%. Dry granulation is therefore selected on the basis of ribbon density and granule particle size control. Roller compaction is performed with roll pressure adjusted to achieve ribbon density of 0.9–1.2 g/cm³, followed by milling through a screen aperture of 0.8–1.5 mm and blending with croscarmellose sodium at 2–4 wt% as disintegrant and colloidal silicon dioxide at 0.2–0.5 wt% as glidant. The lubricated blend is encapsulated on a dosator or tamping-pin machine with fill weight control not exceeding ±3% of target; pin settings are adjusted to avoid in-capsule compaction that would delay disintegration and dissolution. Compliance for the finished capsule is anchored to the ChP 2020 Acetylspiramycin Capsules monograph where available, USP <711> for dissolution, USP <905> for content uniformity, and ICH Q3C (R8) and Q3D (R2) for residual solvent and elemental impurity control. Terminal product types include hard gelatin capsules and hydroxypropyl methylcellulose capsules at 100 mg and 200 mg, typically packaged in aluminum/PVC/Al or Aclar blisters to limit moisture ingress. If the filling suite exceeds 60% RH, pre-drying or humidity-controlled transfer is required because moisture uptake above 2.0% w/w can alter capsule shell brittleness and shift dissolution of the macrolide fill.

Because oral liquid dosing requires a reconstitution step, acetylspiramycin is formulated as dry suspension granules rather than as an aqueous ready-to-use liquid. In single-dose sachets for 100 mg oral administration, the API may represent only 5–10 wt% of total sachet fill mass when fill mass is 1–2 g; in multi-dose dry syrup bottles, the API fraction can be 1–5 wt% due to the larger sucrose or sorbitol vehicle. The granulation process uses a fluid-bed top-spray granulator with a binder solution of pregelatinized starch or povidone K30 sprayed at a rate that maintains product temperature below 40 °C, protecting the acetyl ester from heat-promoted hydrolysis. After granulation, the material is milled to a particle size distribution in which not less than 90% passes a 0.5 mm sieve and retained particles above 0.8 mm are minimized, because oversized granules slow reconstitution in water and cause dose-splitting errors. Xanthan gum or microcrystalline cellulose-carboxymethylcellulose co-processed suspending agents are blended at 0.2–0.5 wt% of final granule mass in a low-shear drum mixer for 10–15 min; flavour and citric acid buffer are added to achieve a reconstituted suspension pH below 6.5. Compliance standards include the ChP 2020 granules monograph, ICH Q3C (R8) for residual ethanol or isopropanol from binder preparation, ICH Q3D (R2) for elemental impurities, and USP <921> for moisture determination. Terminal product types are single-dose aluminum-laminated stick packs and multi-dose amber glass dry syrup bottles requiring reconstitution to 5 mL or 10 mL per dose. Final granule moisture is controlled to ≤2.0% w/w by USP <921> Karl Fischer titration, and packaging is performed at ≤35% RH to prevent caking and failure of redispersion after storage.

Aseptic Powder Filling and Sterile Filtration Boundaries for Injectable Presentations

Injectable presentations of acetylspiramycin are processed as sterile powder for injection when terminal steam sterilization is not feasible because the acetyl ester linkage undergoes accelerated hydrolysis under high-moisture thermal load. Aseptic processing is performed according to EU GMP Annex 1 and 21 CFR 211, with Grade A laminar airflow zones conforming to ISO 14644-1 Class 5 at rest and in operation. For a 200 mg per vial powder-for-injection presentation, the API fraction can exceed 90 wt% if fill weight is limited to 220 mg, leaving 10 wt% or less for pH-adjusting or bulking excipients; if mannitol is employed as a bulking agent in a 1:1 ratio, the API fraction is reduced to 50 wt%. Sterility assurance is anchored to USP <71> and Ph. Eur. 2.6.1, bacterial endotoxin control to USP <85> and Ph. Eur. 2.6.14, particulate matter to USP <788> and Ph. Eur. 2.9.19, and elemental impurities to ICH Q3D (R2). The sterile API is filled into depyrogenated Type I glass vials using a peristaltic or auger filling head under first-air protection, with fill weight monitored by 100% checkweighing at ±1.5% of target. Vials are sealed with lyophilization-grade bromobutyl rubber closures and aluminum flip-off seals. Container closure integrity is verified by validated dye ingress or vacuum decay methods at annual requalification. Terminal product types include powder for injection vials labelled at 100 mg and 200 mg, to be reconstituted with Water for Injection to a concentration of 20–50 mg/mL before injectable administration. Published data on the exact lyophilized excipient matrix for acetylspiramycin is limited; therefore formulators must verify the pH-solubility profile, buffer capacity, and absence of turbidity after reconstitution before process lock.

When acetylspiramycin tablet cores reach a moisture-sensitive packaging step or are intended for pediatric split-dose administration, a functional film coating is applied to mask the bitter macrolide aftertaste and to reduce photodegradation of the active substance. The coating formulation is an aqueous dispersion of hydroxypropyl methylcellulose or polyvinyl alcohol with titanium dioxide or iron oxide opacifier; polymer solids are applied at 2.5–4.5 wt% of the core mass, so a 350 mg core receives between 8.75 mg and 15.75 mg dry coating solids. The coated tablet does not alter the API fraction in the core; the coating addition ratio is therefore expressed relative to core mass rather than as active substance loading. Process control on a perforated pan coater includes inlet air temperature of 60–70 °C, bed temperature of 40–50 °C, spray rate of 6–12 g/min per kg of tablet bed, and pan speed adjusted to maintain tablet surface wetting without overwetting. The coating operation must not expose cores to prolonged bed temperatures above 65 °C, because accelerated acetyl ester hydrolysis can reduce potency and increase free spiramycin-related impurities. Compliance for release testing includes ChP 2020 coated tablet provisions where applicable, USP <711> for dissolution, USP <1216> for friability, and ICH Q3C (R8) for residual organic coating solvents if non-aqueous systems are used. Terminal product types include film-coated tablets with 100 mg and 200 mg strengths, packaged in cold-formed aluminum foil blisters when the API is assigned to tropical climate zones with 30 °C/75% RH long-term storage conditions.